Harle-Tsu (CBD): A Comprehensive Strain Guide

Origins and Breeding History

Harle-Tsu, often written as Harle-Tsu (CBD), emerged from the early-2010s wave of breeder-led efforts to stabilize high-CBD cannabis chemotypes. It is a carefully selected cross of Harlequin and Sour Tsunami, two parent lines with strong reputations for producing CBD-dominant offspring. The project is widely associated with the Southern Humboldt breeding community, where phenotype hunting and lab verification became standard practice to lock in a reliable, low-THC profile.

The timing of Harle-Tsu’s rise coincided with a broader cultural shift toward non-intoxicating cannabis for wellness, particularly in medical markets across the western United States. Early batches quickly gained attention because they routinely tested with CBD levels in the low-to-mid teens and THC often below 1%. This made Harle-Tsu one of the first modern cultivars to offer a consistent, functional CBD experience with minimal psychoactivity.

As CBD-only and CBD-dominant categories matured, Harle-Tsu became a dependable reference point for patients, clinicians, and dispensaries. Its reputation was reinforced by third-party lab results shared by pioneering labs and platforms. Over the years, the strain’s profile spread beyond flower to include tinctures, extracts, and vape cartridges, enabling a wide range of delivery methods for diverse patient needs.

Consumer-facing databases played a key role in documenting Harle-Tsu’s character and availability. Platforms like Leafly cataloged lab-verified test ranges, user-reported effects, and product forms, including entries such as “Harle-Tsu – CBD Disposable Oil Cartridge.” These listings helped standardize expectations for cannabinoid ratios and terpene makeup while guiding consumers toward similar strains using data-driven similarity tools.

By the mid-2010s, Harle-Tsu was frequently referenced in clinics and caregiver communities as a go-to CBD cultivar. Its stable reputation arose not just from strong parents, but from thoughtful selection—the act of growing many plants, testing each, and keeping only the phenotypes with the desired CBD-rich chemotype. That rigorous approach continues to define how cultivators maintain the Harle-Tsu name today.

Genetic Lineage and Chemotype Inheritance

Harle-Tsu’s parentage—Harlequin × Sour Tsunami—stacks the deck for CBD dominance. Harlequin is a well-known CBD line with ancestry often traced to landrace influences from Colombia, Thailand, and Switzerland, brought together to favor a balanced, therapeutic chemotype. Sour Tsunami, developed by Lawrence Ringo’s breeding efforts, was one of the first American strains intentionally bred for CBD rather than THC.

From a biochemical perspective, CBD dominance in cannabis is governed primarily by the expression of CBDA synthase relative to THCA synthase. Breeding two CBD-forward parents increases the odds that offspring will express the “Type III” chemotype—high CBD with very low THC. In practical terms, ethical breeders germinate large seed populations and select only those plants that consistently test with a strong CBD:THC ratio, ideally above 10:1 and frequently 20:1 or higher.

In an F1 cross of two parents carrying CBD-favoring alleles, the offspring can segregate into a spectrum of chemotypes. Without selection, a population can show a mixture of Type I (THC-dominant), Type II (mixed), and Type III (CBD-dominant) plants due to Mendelian inheritance at the synthase loci. With the Harle-Tsu project, breeders targeted Type III phenotypes and culled the rest, a process that can involve testing 50–200 seedlings to isolate a handful of keepers.

The result is a cultivar name that refers to a chemotype more than to a single genetic clone, though many growers do maintain specific, tested mother plants. Clonal propagation preserves the proven CBD profile by bypassing genetic reshuffling from seed. This is why reputable Harle-Tsu vendors often specify “clone-only selection” or share lab data tied to a particular batch.

Consumers benefit from this backbone of selection by getting more consistent effects. When Harle-Tsu is grown from a verified mother, test results commonly fall within predictable ranges. That predictability is the foundation of its reputation as a CBD cornerstone in modern dispensary menus.

Visual Morphology and Bud Structure

Harle-Tsu plants typically express hybrid vigor with a slight sativa-leaning structure—medium internodal spacing, strong lateral branching, and a balanced apical dominance. In controlled indoor conditions, plants often finish between 70–110 cm tall after training, while outdoor specimens can reach 150–200 cm depending on pot size, soil fertility, and light exposure. The leaf morphology usually shows medium-width leaflets, reflecting its hybrid pedigree.

Buds present as dense, resin-frosted clusters with a calyx-to-leaf ratio that makes trimming manageable without being overly airy. The coloration tends toward olive green with occasional lime highlights, accented by amber-orange pistils as maturity approaches. Under magnification, trichomes are abundant and primarily capitate-stalked, indicating robust resin production despite low THC.

As plants ripen, top colas can stack into elongated spears, while secondary branches carry symmetrical flower sites. Average indoor yields range from 350–500 g/m² under efficient lighting, with top-tier, dialed-in grows reporting 500–600 g/m². Outdoor yields vary widely, but 400–900 g per plant is common with ample sun and a 25–50 L container or in-ground beds.

Growers often notice that Harle-Tsu retains a slightly more pliable bud feel after drying, a trait linked to its resin and terpene composition. Proper slow-drying is essential to preserve the subtle aromatics and prevent chlorophyll harshness from overshadowing its delicate flavor. A final moisture content around 10–12% and water activity 0.55–0.65 is a reliable benchmark for quality.

Visually, Harle-Tsu flowers won’t typically present the deep purples seen in anthocyanin-heavy cultivars unless grows encounter significant nighttime temperature drops. However, the crystals are conspicuous, lending a premium sheen to the cured buds. In photographs, that frosted finish often belies the strain’s gentle psychoactivity, reminding buyers that visual frost does not equate to high THC.

Aroma Nuances and Volatile Compounds

Harle-Tsu’s aroma is clean and comforting, leaning into forested, herbal notes with subtle sweetness. Common descriptors include pine, fresh wood, sweet citrus, and a hint of pepper or spice. Many batches also show a light grassy-tea nuance typical of myrcene-forward profiles.

Lab data compiled across dispensaries frequently places myrcene, beta-caryophyllene, and alpha-pinene among the top terpenes in Harle-Tsu. Typical total terpene content runs around 1.0–2.5% by weight, with standout samples pushing closer to 3.0% under careful cultivation and gentle post-harvest handling. Myrcene commonly appears in the 0.3–0.9% range, while alpha-pinene and beta-caryophyllene often register 0.1–0.6% each.

Supporting terpenes such as humulene, ocimene, and limonene show up in the 0.05–0.3% window. Humulene adds a dry, woody note; ocimene can impart a green, slightly sweet herbal accent; and limonene contributes a soft citrus lift. The final aromatic impression is cohesive rather than loud, aligning with the strain’s understated effect profile.

Consumers frequently note that the nose “opens up” after a gentle grind and a short rest. Allowing ground flower to sit for 60–90 seconds before packing can bloom the pine-citrus aromatics without excessively volatilizing the lightest fractions. In sealed packaging, the aroma remains moderate but distinct, with terpene preservation correlating strongly with storage at 15–20°C and 55–62% relative humidity.

Platforms like Leafly characterize Harle-Tsu’s aromatic signature within data-driven maps that cluster strains by terpene similarity. That “we used science to find strains with similar terpenes and effects” approach helps users identify alternatives when Harle-Tsu is unavailable. Neighboring profiles often include other myrcene/pinene/caryophyllene-forward CBD cultivars, enabling a consistent sensory and functional experience.

Flavor Profile and Consumption Methods

Harle-Tsu’s flavor mirrors its aroma: pine-forward with soft citrus, sweet wood, and a light peppery finish. Vaporization highlights the citrus top notes and alpha-pinene’s bright, resinous character, while combustion tends to emphasize caryophyllene’s pepper and humulene’s woody dryness. The overall palate is smooth when properly cured, with minimal harshness and a clean aftertaste.

For dry herb vaporizers, a temperature window of 175–190°C (347–374°F) preserves myrcene and pinene while fully activating CBD. Many users step temperature in two stages—starting at ~180°C to savor flavor, then finishing at ~195°C to maximize extraction. Combustion remains effective for fast onset, though it sacrifices some monoterpenes and can obscure the strain’s nuance.

Edibles, tinctures, and oils made from Harle-Tsu deliver consistent CBD dosing with minimal intoxication. In oral forms, onset typically occurs in 30–90 minutes, with peak effects around 2–3 hours and total duration 4–8 hours depending on dose and individual metabolism. Sublingual tinctures can move the onset earlier by 15–30 minutes compared to swallowed edibles.

The market often features Harle-Tsu in concentrates and cartridges tuned for CBD-heavy use. Leafly listings have included products like a Harle-Tsu CBD Disposable Oil Cartridge, reflecting demand for portable, discrete dosing with predictable ratios. In concentrates, users should verify that THC remains low if minimal psychoactivity is desired; reputable vendors provide batch-specific COAs.

Dose-wise, a single inhalation from a standard vape cartridge can deliver roughly 1–3 mg CBD, depending on device output and formulation. For flower, a 0.25 g bowl of 12% CBD Harle-Tsu contains approximately 30 mg CBD, though extraction efficiency with combustion is typically 30–60%. Oral doses commonly start at 10–20 mg CBD for new users and scale to 25–100 mg for targeted relief, titrating based on response.

Cannabinoid Profile and Lab-Verified Ratios

Harle-Tsu is renowned for CBD-dominant lab results, with many verified batches landing between 10–20% CBD by dry weight. THC is typically low, often 0.4–1.5%, which yields common CBD:THC ratios ranging from 10:1 to 30:1. Especially CBD-heavy selections occasionally test above 20% CBD with THC below 1%, producing ratios that exceed 20:1.

To translate those percentages into practical dosing: one gram of flower at 12% CBD contains roughly 120 mg of decarboxylated CBD potential. After combustion or vaporization, real-world delivery efficiency varies, with inhaled bioavailability estimated around 10–35% depending on technique and device. This means a single 0.25 g session of 12% CBD flower may deliver 9–26 mg CBD to systemic circulation in many cases.

Minor cannabinoids commonly observed in Harle-Tsu include CBGA and CBC in the 0.1–0.7% range combined, with occasional trace CBDV. While minor cannabinoid levels are modest, they contribute to the entourage effect and may enhance perceived efficacy through complementary pharmacology. Acidic precursors like CBDA can be prominent in raw flower, and low-temperature preparations that retain CBDA are sought by some consumers for specific use cases.

Test variability arises from phenotype differences, cultivation conditions, harvest timing, and post-harvest handling. Standard deviations of ±1–3 percentage points in CBD are not unusual across producers, even when using the same clone, due to environment and curing factors. Consistency improves when growers control light intensity, nutrition, and drying protocols while harvesting at identical maturity windows.

Consumer databases and lab networks have helped establish realistic expectations for Harle-Tsu’s ratio. Leafly’s public-facing strain data consistently situates Harle-Tsu in the high-CBD, low-THC category, aligning with dispensary COAs from multiple markets. When purchasing, always verify batch-specific test results, especially if a patient requires THC below a certain threshold for workplace or legal reasons.

Terpene Spectrum and Mechanistic Interplay

Harle-Tsu’s terpene spectrum typically centers on myrcene, alpha-pinene, and beta-caryophyllene, with humulene, ocimene, and limonene as notable complements. Aggregate data place myrcene around 0.3–0.9% by weight in many batches, supporting a calm, soothing baseline. Alpha-pinene often ranges 0.1–0.4%, contributing alertness and a sense of respiratory openness.

Beta-caryophyllene (BCP) tends to land around 0.2–0.6% and is pharmacologically distinct as a dietary cannabinoid with selective CB2 receptor agonism. Preclinical research reports BCP’s CB2 activity with EC50 values in the low micromolar range, mediating anti-inflammatory and analgesic effects via peripheral immune pathways. This aligns with user reports that Harle-Tsu can reduce soreness and tension without heavy sedation.

Humulene, typically 0.1–0.3%, layers a dry, woody note and has been studied for anti-inflammatory synergy with caryophyllene. Limonene, in the 0.1–0.4% window, can buoy mood and add a bright citrus top end. Ocimene, sometimes 0.05–0.2%, adds green-herbal sweetness and is volatile, making careful post-harvest handling especially important to preserve it.

Mechanistically, CBD interacts with multiple targets—5-HT1A receptors, TRPV channels, PPARγ, and GPR55 modulation among others—while terpenes may modulate neurotransmission and inflammation. A pinene-forward profile, for example, has been associated with acetylcholinesterase inhibition, which some users experience as improved mental clarity. Meanwhile, myrcene’s reputed muscle-relaxant qualities can promote body comfort without locking users to the couch.

Total terpene content correlates with perceived aroma intensity and may relate to effect depth. Batches measuring 1.5–2.5% total terpenes are frequently described as more flavorful and functionally robust. Growers achieve these levels by optimizing late-flower environment and employing slow, cool drying to minimize volatilization.

Experiential Effects and Functional Use

Harle-Tsu is designed for clarity and calm rather than intoxication, making it a daytime-friendly CBD cultivar. Users consistently report a clear headspace, mild body ease, and notably low anxiety reactivity even in stressful settings. The strain’s minimal THC content keeps euphoria and time distortion muted while still delivering a perceptible shift toward relaxation.

Onset depends on delivery method. Inhalation produces effects within 2–10 minutes, peaking in 30–60 minutes and fading over 2–4 hours. Oral ingestion begins within 30–90 minutes, peaks near 2 hours, and can last 4–8 hours, with higher doses extending duration.

The mood profile skews neutral-to-positive, often described as composed, centered, and quietly uplifted. At modest inhaled doses, many users report improved task focus without jitters, which aligns with alpha-pinene’s contribution to alertness. In the body, low-level muscle relaxation and reduced soreness are common without the heavy sedation some indica-leaning THC strains impart.

Side effects are typically mild and include dry mouth, dry eyes, and occasional lightheadedness at higher doses, especially in naïve users. Notably, CBD can interact with cytochrome P450 enzymes (e.g., CYP3A4 and CYP2C19), which may alter the metabolism of certain prescription drugs. Anyone on medications with a narrow therapeutic window should consult a clinician before initiating high-dose CBD.

Compared to balanced CBD:THC strains, Harle-Tsu minimizes impairment risk, making it a frequent recommendation for first-time medical users. Its consistent CBD ratios and mellow sensory profile contribute to stable outcomes over repeat sessions. For users who appreciate data-b